S&P 500   3,000.76 (+0.16%)
DOW   26,880.13 (+0.34%)
QQQ   191.92 (+0.04%)
AAPL   242.64 (+1.12%)
FB   185.14 (+1.53%)
MSFT   136.19 (-0.14%)
GOOGL   1,255.20 (+1.13%)
AMZN   1,765.37 (-0.02%)
CGC   21.05 (-0.47%)
NVDA   194.10 (-0.77%)
MU   44.14 (-1.16%)
BABA   168.74 (-0.68%)
GE   9.02 (-0.44%)
TSLA   254.23 (-0.53%)
AMD   31.37 (-0.44%)
T   38.11 (-0.18%)
F   9.03 (-0.44%)
ACB   3.58 (+0.00%)
NFLX   271.73 (+1.89%)
BAC   31.34 (+0.45%)
GILD   65.92 (+0.09%)
DIS   131.90 (-0.38%)
S&P 500   3,000.76 (+0.16%)
DOW   26,880.13 (+0.34%)
QQQ   191.92 (+0.04%)
AAPL   242.64 (+1.12%)
FB   185.14 (+1.53%)
MSFT   136.19 (-0.14%)
GOOGL   1,255.20 (+1.13%)
AMZN   1,765.37 (-0.02%)
CGC   21.05 (-0.47%)
NVDA   194.10 (-0.77%)
MU   44.14 (-1.16%)
BABA   168.74 (-0.68%)
GE   9.02 (-0.44%)
TSLA   254.23 (-0.53%)
AMD   31.37 (-0.44%)
T   38.11 (-0.18%)
F   9.03 (-0.44%)
ACB   3.58 (+0.00%)
NFLX   271.73 (+1.89%)
BAC   31.34 (+0.45%)
GILD   65.92 (+0.09%)
DIS   131.90 (-0.38%)
Log in

BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

$200.69
+0.01 (+0.00 %)
(As of 10/23/2019 11:08 AM ET)
Today's Range
$200.36
Now: $200.69
$201.98
50-Day Range
$184.69
MA: $197.53
$204.23
52-Week Range
$132.75
Now: $200.69
$217.15
Volume741 shs
Average Volume154,681 shs
Market Capitalization$7.60 billion
P/E Ratio52.81
Dividend Yield0.63%
Beta1.21
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:TECH
CUSIP87837710
Phone612-379-8854

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$714.01 million
Cash Flow$5.89 per share
Book Value$30.78 per share

Profitability

Net Income$96.07 million

Miscellaneous

Employees2,250
Market Cap$7.60 billion
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable

Receive TECH News and Ratings via Email

Sign-up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.


BIO-TECHNE (NASDAQ:TECH) Frequently Asked Questions

What is BIO-TECHNE's stock symbol?

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

How often does BIO-TECHNE pay dividends? What is the dividend yield for BIO-TECHNE?

BIO-TECHNE announced a quarterly dividend on Tuesday, August 6th. Shareholders of record on Friday, August 16th will be given a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, August 15th. View BIO-TECHNE's Dividend History.

How were BIO-TECHNE's earnings last quarter?

BIO-TECHNE Corp (NASDAQ:TECH) announced its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.25 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.17 by $0.08. The biotechnology company earned $191.66 million during the quarter, compared to analyst estimates of $196.37 million. BIO-TECHNE had a return on equity of 13.20% and a net margin of 13.45%. The company's quarterly revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business earned $1.34 EPS. View BIO-TECHNE's Earnings History.

When is BIO-TECHNE's next earnings date?

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

How can I listen to BIO-TECHNE's earnings call?

BIO-TECHNE will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for TECH?

6 brokers have issued twelve-month price targets for BIO-TECHNE's shares. Their predictions range from $165.00 to $270.00. On average, they expect BIO-TECHNE's stock price to reach $206.80 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

What is the consensus analysts' recommendation for BIO-TECHNE?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

Has BIO-TECHNE been receiving favorable news coverage?

News headlines about TECH stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. BIO-TECHNE earned a news sentiment score of 0.6 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for BIO-TECHNE.

Are investors shorting BIO-TECHNE?

BIO-TECHNE saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 799,800 shares, an increase of 8.1% from the August 15th total of 739,700 shares. Based on an average daily volume of 166,700 shares, the days-to-cover ratio is currently 4.8 days. Currently, 2.1% of the shares of the company are short sold. View BIO-TECHNE's Current Options Chain.

Who are some of BIO-TECHNE's key competitors?

What other stocks do shareholders of BIO-TECHNE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Amgen (AMGN), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH) and Illumina (ILMN).

Who are BIO-TECHNE's key executives?

BIO-TECHNE's management team includes the folowing people:
  • Mr. Charles R. Kummeth, CEO, Pres & Director (Age 59)
  • Mr. James T. Hippel, Sr. VP of Fin. & CFO (Age 48)
  • Ms. Brenda S. Furlow, Gen. Counsel, Sec. & Chief Compliance Officer (Age 61)
  • Mr. N. David Eansor, Pres of Protein Sciences Segment (Age 58)
  • Mr. Gerry Andros, VP of Sales and Marketing

Who are BIO-TECHNE's major shareholders?

BIO-TECHNE's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Riverbridge Partners LLC (1.05%), Candriam Luxembourg S.C.A. (0.34%), Stephens Investment Management Group LLC (0.23%), Summit Creek Advisors LLC (0.22%), Envestnet Asset Management Inc. (0.06%) and Palisade Asset Management LLC (0.04%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

Which major investors are selling BIO-TECHNE stock?

TECH stock was sold by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Riverbridge Partners LLC, Pacer Advisors Inc., Brookstone Capital Management, Palisade Asset Management LLC, Meeder Asset Management Inc., NEXT Financial Group Inc and State of Michigan Retirement System. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

Which major investors are buying BIO-TECHNE stock?

TECH stock was bought by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Ascension Asset Management LLC, Summit Creek Advisors LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Tributary Capital Management LLC, Navellier & Associates Inc and Clarus Wealth Advisors. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

How do I buy shares of BIO-TECHNE?

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIO-TECHNE's stock price today?

One share of TECH stock can currently be purchased for approximately $200.87.

How big of a company is BIO-TECHNE?

BIO-TECHNE has a market capitalization of $7.61 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

What is BIO-TECHNE's official website?

The official website for BIO-TECHNE is http://www.techne-corp.com/.

How can I contact BIO-TECHNE?

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]


MarketBeat Community Rating for BIO-TECHNE (NASDAQ TECH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  290 (Vote Outperform)
Underperform Votes:  315 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about BIO-TECHNE and other stocks. Vote "Outperform" if you believe TECH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TECH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2019 by MarketBeat.com Staff

Featured Article: Float

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel